For US Healthcare Professionals only

Mozobil® (Plerixafor) Injection logo

Menu

Illustration of cells with blue nuclei with a red and black background.

About Mozobil® (Plerixafor) Injection

Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.

Mozobil is a first in class CXCR4 receptor antagonist.1

Sanofi Is Committed to Helping Patients

Sanofi Patient Connection® is a program designed to assist patients through 3 main types of patient support:

Blue arrow icon.

Patient Assistance Connection: Providing patients who meet eligibility criteria with their prescribed medications at no cost

Blue arrow icon.

Reimbursement Connection: Supporting patients and providers in determining insurance coverage, including benefit verification, prior authorization, and appeals assistance

Blue arrow icon.

Resource Connection: Helping identify additional appropriate resources and support for program patients

Icon of a prescription scroll with an Rx symbol and pencil.

PATIENT ASSISTANCE CONNECTION

Provides certain Sanofi prescription medications at no cost to patients who meet program eligibility requirements

Learn about eligibility
Icon of a dollar sign with a circular arrow.

INSURANCE COVERAGE REVIEW

Supports you in determining your insurance coverage for Sanofi medications when applying for assistance through Sanofi Patient Assistance Connection*

Learn more
Icon of a magnifying glass with a checkmark inside.

RESOURCE CONNECTION

Helps identify additional resources and support for program patients and caregivers as appropriate

Find support

Important Safety Information

  • Mozobil is contraindicated in patients with a history of hypersensitivity to Mozobil.
  • Anaphylactic shock and serious hypersensitivity reactions, some of which have been life-threatening, have occurred in patients receiving Mozobil. Observe patients for signs and symptoms of hypersensitivity during and after Mozobil administration for at least 30 minutes and until clinically stable. Only administer Mozobil when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.
  • Mozobil may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. Therefore, Mozobil is not intended for HSC mobilization and harvest in patients with leukemia.
  • Mozobil in conjunction with filgrastim increases circulating leukocytes and HSC populations. White blood cell counts should be monitored during treatment.
  • Thrombocytopenia has been observed in patients receiving Mozobil. Platelet counts should be monitored in patients who receive Mozobil and then undergo apheresis.
  • In patients treated with Mozobil in combination with filgrastim for HSC mobilization, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. The effect of potential reinfusion of tumor cells has not been well-studied.
  • Postmarketing cases of splenic enlargement and/or rupture have been reported following the administration of Mozobil in conjunction with filgrastim. Individuals receiving Mozobil in combination with filgrastim who report left upper abdominal pain and/or scapular or shoulder pain should be evaluated for splenic integrity.
  • Mozobil can cause fetal harm when administered to a pregnant woman. Plerixafor is teratogenic in animals. Plerixafor administration to pregnant rats during organogenesis resulted in embryo-fetal mortality, structural abnormalities, and alterations to growth at exposures approximately 10 times the exposure at the recommended human dose. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use an effective form of contraception during treatment with Mozobil and for one week after the final dose.
  • There are no data on the presence of plerixafor in human milk, the effect on the breastfed child, or the effect on milk production. Because of the potential serious adverse reactions in the breastfed child, advise females that breastfeeding is not recommended during treatment with Mozobil and for one week after the final dose.
  • Males treated with Mozobil should use effective contraception during treatment and for one week after cessation of treatment.
  • The most common adverse reactions (=10%) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), fatigue (27%), injection site reactions (34%), headache (22%), arthralgia (13%), dizziness (11%), and vomiting (10%). The majority of these adverse reactions were Grade 1 or 2.

Indication

MOZOBIL® (plerixafor) injection is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).

Click here for Full Prescribing Information for Mozobil.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

*Sanofi Patient Assistance Connection can provide certain Sanofi prescription medications at no cost if you meet program eligibility requirements.

Important Safety Information

Indication

REFERENCE:

  1. Mozobil [prescribing information]. Cambridge, MA: Genzyme Corporation.

Mozobil, Sanofi Patient Connection and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2012603-v4.0-05/2025

Back to top
sanofi_campus_logo
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContact
© 2025 Sanofi. All rights reserved.